15
Growth Score
pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4283997
Agalimmune was established in 2013. Its shareholders include Loxbridge Research LLP
About the Company
Agalimmune was established in 2013. Its shareholders include Loxbridge Research LLP and Animatrix Capital LLP which invest in innovative medical technologies. Agalimmune is located in London, UK and California, USA.
Agalimmune has licensed the Alphaject™ immunotherapeutic technology from the University of Massachusetts Medical School, Worcester,
MA (USA) where it was researched and developed by a team, led by Professor Uri Galili. The goal of Alphaject™ therapy is to convert the injected tumor into a vaccine that “instructs” the immune system of patients with solid tumors to recognize metastatic tumor cells and destroy them. This treatment may also bring about a long lasting protective anti-tumor immune response.
